Priothera Appoints Dr. Jens Hasskarl as New CMO for AML Therapy Push

Company - People | May 06, 2025 | HealthCap Venture Capital

Priothera Appoints Dr. Jens Hasskarl as New CMO for AML Therapy Push

Priothera Ltd., a biopharmaceutical company engaged in the development of innovative treatments for hematologic malignancies, has appointed Dr. Jens Hasskarl as its new Chief Medical Officer. Dr. Hasskarl will lead the Phase 3 MO-TRANS study for mocravimod, a novel sphingosine 1 phosphate (S1P) receptor modulator aimed at enhancing the effectiveness of allogeneic hematopoietic cell transplantation (allo-HCT) in treating acute myeloid leukemia (AML). With a vast background in clinical development and having served in strategic roles in major pharmaceutical firms such as Novartis and Celgene, Dr. Hasskarl brings essential experience to Priothera. His role will focus on directing the clinical execution and interacting with global regulatory bodies. Dr. Hasskarl's appointment comes at a pivotal time as Priothera looks to advance its clinical programs and ultimately bring the promising drug to AML patients globally.

Sectors

  • Biopharmaceuticals
  • Biotechnology
  • Healthcare

Geography

  • Ireland – Priothera's base of operations is located in Dublin, Ireland, making it a relevant geography for company activities.
  • France – The announcement was also associated with Saint-Louis, France, implying potential dual operations or collaborations.
  • Germany – Dr. Jens Hasskarl has ties to Germany via academic pursuits and professional background, contributing his global expertise to Priothera.

Industry

  • Biopharmaceuticals – This industry is relevant as Priothera is engaged in the development of biopharmaceutical products targeting hematologic malignancies.
  • Biotechnology – The biotechnology sector applies to Priothera's focus on developing a novel S1P receptor modulator, indicative of advanced scientific processes.
  • Healthcare – The healthcare sector is pertinent due to the focus on treatments for hematologic conditions such as AML.

Financials

    Participants

    NameRoleTypeDescription
    Priothera Ltd.Target CompanyCompanyBiopharma company developing mocravimod for hematologic malignancies.
    HealthCap Venture CapitalInvestorCompanyPrivate equity firm providing venture capital to Priothera.
    Dr. Jens HasskarlChief Medical OfficerPersonNewly appointed CMO responsible for leading the Phase 3 clinical trial of mocravimod.
    Dr. Florent GrosCo-Founder and CEO of PriotheraPersonProvides a strategic vision for Priothera as the company advances its lead product.
    Dr. Elisabeth KueenburgFormer Chief Medical OfficerPersonPrevious CMO of Priothera, praised for her contributions.